Absci’s shares moved marginally (+0.5%) following its Q1 2026 update, indicating that while investors found the reported progress in the ABS-201 clinical program broadly in line with what was expected, there was no clear catalyst to drive a meaningful re-rate.

• The Phase I/IIa HEADLINE trial of ABS-201 remains on track, with preliminary safety, tolerability, and PK data expected next month and interim efficacy data due in H2 2026.
• ABS-201 aims to create a novel biologic category for androgenic alopecia, targeting the prolactin receptor with a differentiated mechanism not competing directly with existing treatments like minoxidil.
• The company is advancing a Phase II endometriosis study slated to begin in Q4 2026, supported by a new Endometriosis Clinical Advisory Board with notable academic leaders.
• Absci is expanding its prolactin-targeted pipeline with ABS-202, an anti-prolactin receptor antibody for an undisclosed inflammation and immunology indication.
• Focus remains on leveraging its AI-driven platform and expertise to develop differentiated therapeutic assets in complex, underserved indications.